R. Samuel Herron PhD

Samuel Herron is a science advisor in Goodwin’s Intellectual Property Litigation practice within the firm’s Litigation department. Since joining in 2022, he contributes to the firm’s work in patent litigation, patent opinions, and due diligence with a focus in the areas of biotechnology and pharmaceuticals.

Over the past year, Sam has been involved in various stages of patent litigation, including discovery and pretrial proceedings.

Sam received his Doctorate in Philosophy from the University of Pittsburgh School of Medicine, wherein his research focused on mRNA processing. In his dissertation work, Sam utilized molecular biology and genetic techniques to characterize the regulation of mRNA isoform expression by the mTOR pathway, an essential signaling pathway in cellular growth. Sam has additional research experience with gene editing technology, next generation sequencing, and viral vector delivery systems.

Sam has published scientific articles in peer-reviewed journals and textbooks, including ELife and Methods in Enzymology. Sam has also published on policy topics including work published in the Journal of Science Policy & Governance and Governance. Sam is an editor and contributor to the firm’s award-winning biosimilars blog, Big Molecule Watch.